Delivery Order SPE2DB25D3021-SPE2DB25FQZBE
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,847.74 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement requirements. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units. This firm fixed-price delivery order, valued at $3,819.30, represents a competitive award with no set-aside designation and carries an ultimate completion date of July 28, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. This competitive delivery order, valued at $136,414.55 under a firm fixed price arrangement, is scheduled for completion by July 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this delivery order was competitively...
- The Defense Logistics Agency awarded a delivery order valued at $10,772.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 25, 2025, with completion expected by July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a procurement of pharmaceutical inventory supporting military healthcare operations. The contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $15,876.35 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed price contract, with an ultimate completion date of July 21, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,602.94 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The contractor, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 21, 2025, with a completion date of July 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a small-value pharmaceutical supply transaction. The award was placed of performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order operates...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for supply of RINVOQ ER 15 mg tablets in quantities of 30, with a ceiling value of $17,975.65. This is a firm fixed-price delivery order with no set-aside designation, awarded on a competitive basis. The contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 24, 2025. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a $12,578.87 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion required by July 29, 2025. This is a firm fixed price, non-set-aside contract with performance location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion comprehensive...
- SPE2DB25D3021Indefinite Delivery Contract
- SPE2DB25D3021-SPE2DB25FQZBEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $10,858.62. This is a non-set-aside, competitively awarded delivery order that will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical distributor within the federal medical procurement system. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum potential value of $999,999,999.00 through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide, including customers such as the Defense Health Agency and U.S. Coast Guard. The company's federal contract portfolio demonstrates consistent performance in delivering diverse pharmaceutical products across multiple therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.9k | 7/21/25 |